CEO of Ligand Pharmaceuticals Inc (LGND, Financial) John L Higgins sold 34,500 shares of LGND on 08/17/2018 at an average price of $241.96 a share. The total sale was $8.3 million.
Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand Pharmaceuticals Inc has a market cap of $5.23 billion; its shares were traded at around $247.98 with a P/E ratio of 51.13 and P/S ratio of 26.22. Ligand Pharmaceuticals Inc had annual average EBITDA growth of 73.90% over the past five years.
CEO Recent Trades:
- CEO John L Higgins sold 34,500 shares of LGND stock on 08/17/2018 at the average price of $241.96. The price of the stock has increased by 2.49% since.
Directors and Officers Recent Trades:
- Director Jason Aryeh sold 27,942 shares of LGND stock on 08/17/2018 at the average price of $241.94. The price of the stock has increased by 2.5% since.
- Director Todd C Davis sold 9,000 shares of LGND stock on 08/17/2018 at the average price of $239.78. The price of the stock has increased by 3.42% since.
- Director Sunil Patel sold 42,287 shares of LGND stock on 08/16/2018 at the average price of $240.05. The price of the stock has increased by 3.3% since.
For the complete insider trading history of LGND, click here
.
